Asthma in Pregnancy: A Review of Current Evidence

Research on asthma in pregnancy has highlighted the complex interactions between hormone-mediated and physical changes to the respiratory system, comorbidities, and treatment options. According to a study published in Allergy, asthma is a common chronic disease affecting pregnant women worldwide, with varying prevalence and unpredictable outcomes. The study emphasized the need for more research on the safety of biologics such as omalizumab and dupilumab in pregnancy, given the increased risk of maternal and fetal adverse outcomes due to uncontrolled asthma and medication non-adherence.

Key Takeaways:

• Asthma is a common chronic disease affecting pregnant women worldwide, with variable prevalence and unpredictable outcomes.
• Hormonally mediated and physical changes to the respiratory system occur during pregnancy and can impact asthma status unpredictably.
• Increased maternal and fetal adverse outcomes are observed with uncontrolled asthma, making medication adherence crucial.
• Certain comorbidities, particularly metabolic comorbidities, are more common in pregnant women with asthma and impact asthma and pregnancy outcomes.
• Omalizumab and dupilumab have shown reassuring observational data regarding their safety in pregnancy, but more studies are needed.
• Medication non-adherence increases in pregnancy due to concerns regarding the effects of medications on the developing fetus.
• Comorbidities, such as metabolic comorbidities, are increasingly understood to impact asthma and pregnancy outcomes.
• The review highlights the need for further research on asthma in pregnancy, including the safety of biologics and the impact of comorbidities on outcomes.

Statistics:

• Asthma affects approximately [insert percentage] of pregnant women worldwide.
• Uncontrolled asthma increases the risk of maternal and fetal adverse outcomes by [insert percentage].
• Medication non-adherence is a major contributor to loss of asthma control in pregnant women, with [insert percentage] of women reporting concerns regarding medication safety.
• Omalizumab and dupilumab have shown reassuring observational data regarding their safety in pregnancy, with [insert number] of women using these medications without adverse outcomes.
• Metabolic comorbidities are more common in pregnant women with asthma, affecting [insert percentage] of women.

Sources:

• Asthma in Pregnancy. Allergy, 2025. Allergy can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.
• Jensen, M. E., Denton, E., Brew, B. K., Hew, M., & Murphy, V. E. (2025). Asthma in Pregnancy. Allergy, 1449. doi: 10.1111/all.14688
• Allergy can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Allergy - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1398-9995)